Hong Kong-listed innovative drug stocks gained ground, with Tongyuan Kang Pharmaceutical rising more than 7%, while Lepu Bio, Shijiazhuang Pharmaceutical Group, and CanSino Biologics each rose more than 3%, and Kelun Biotech and Hansoh Pharmaceutical each rose more than 2%.